The Interplay of Disease Modifying Anti Rheumatic Drugs and Tuberculin Skin Test.
DMARD
Rheumatoid arthritis
TST
anergic.
latent tuberculosis
poly-arthritis
Journal
Current reviews in clinical and experimental pharmacology
ISSN: 2772-4336
Titre abrégé: Curr Rev Clin Exp Pharmacol
Pays: Netherlands
ID NLM: 9918227368306676
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
08
2020
revised:
03
11
2020
accepted:
16
11
2020
pubmed:
5
1
2021
medline:
5
4
2022
entrez:
4
1
2021
Statut:
ppublish
Résumé
The study was conducted to determine whether synthetic Disease-Modifying Anti Rheumatic Drugs (DMARDs) suppress the latency of Tuberculosis (TB) infection in Rheumatoid Arthritis (RA) patients along with other variables. This was done through Tuberculin Skin Test (TST) using purified protein derivative (PPD) in a cohort of RA patients. The TST was taken positive when induration post-PPD injection was ≥ 5mm and negative or anergic when it was < 5mm. We included 100 patients (N = 100). The prevalence of positive TST was 36%, while 64% presented a negative result. Negative TST was significantly associated with steroid usage (39.4%, 95% CI: 28.4%-51.4%). Anergic (TST negative) and non-anergic (TST positive) patients were separated into groups, and a new analysis was conducted with elaboration on DMARDs used. The use of steroids was associated with TST negativity, The same is not true with use of methotrexate or other DMARDs. Thus TST should be interpreted with caution, especially before starting biologicals.
Identifiants
pubmed: 33390147
pii: CCP-EPUB-112910
doi: 10.2174/1574884715999201231201538
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-356Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.